Translation of a bismuth-gadolinium nanoparticle for MR-guided radiation therapy

Ended Project Grant Awarded Last action

Award ID
R01CA240804
Recipient
Awarding agency
Obligated
$5,891,489

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date
Originally
Funding
  • $5,293,232.00 Federal
  • $598,257.00 Non-federal
Place of performance
Massachusetts, USA

Award details come from USAspending.gov.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $29,801 $0
Amendment $536,452 $0
Amendment $536,452 $0
Amendment $593,049 $0
Amendment $593,049 $0
Amendment $593,049 $0
Amendment $594,964 $0
Amendment $598,257 $0
Amendment $598,257 $598,257
Original award $619,902 $0
Show all 11

Subawards

Subrecipient Amount Awarded
NH Theraguix NH TherAguix is a clinical pharmaceutical company specializing in the development of nanomedicine in oncology for imaging and radiotherapy. NH TherAguix (NHT)… $76,545
Ezus Lyon The aim of ILM during the NIH program is to synthesize and characterize the Bi-AGuIX nanoparticlesthat are used in the proposal for MRI and… $76,545

Quick answers

Who received award R01CA240804?

R01CA240804 was awarded to Dana-Farber Cancer Institute, Inc. by National Cancer Institute (National Institutes of Health) on March 1, 2020.

How much is award R01CA240804 worth?

$5,891,489 has been obligated on R01CA240804: $5,293,232 in federal funding and $598,257 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login